Department of Cancer Research

Projects

Projects per year 2010 2017 2019 2020 2021 2022 2023 2029

• 14 Not started
• 56 Active
• 78 Finished

Projects per year

Search results

• Active

  CANBIO2 (Eleonora Campus): Elucidating the role of the IRG1/ACOD1-itaconate axis in TAMs polarization in glioblastoma

  Michelucci, A. & Campus, E.

  FNR - Fonds National de la Recherche

  15/09/23 → 14/09/27

  Project: Research

  • glioblastoma 100%
  • bioinformatics 87%
  • itaconic acid 70%
  • phenotype 60%
  • lymphocyte count 55%

• CANBIO2 (Ana Catarina Almeida): Harnessing DNA repair factors to promote an innate immune response against glioblastoma

  Van Dyck, E. & Almeida, A. C.

  FNR - Fonds National de la Recherche

  1/09/23 → 31/08/27

  Project: Research

  • DNA Repair 100%
  • Innate Immunity 74%
  • Glioblastoma 66%
  • Macrophages 44%
  • Phagocytosis 31%

• ASH AWARD_2023: American Society of Hematology Global Research Award

  Morande, P. E.

  American Association of Hematology

  1/08/23 → 31/07/26

  Project: Research

• CCI4EU: Strengthening research capacities of comprehensive cancer infrastructures

  Niclou, S. & Michel, T.

  1/05/23 → 30/04/26

  Project: Research

  • neoplasms 100%
  • education programs 61%
  • research support 34%
  • research projects 28%
  • infrastructure 28%

• IPerGlio: Improving personalized glioblastoma care by intertwined immunomics and artificial intelligence approaches

  Cosma, A. & Nazarov, P.

  FNR - Fonds National de la Recherche

  1/04/23 → 31/03/26

  Project: Research

• MONO-GLIO: Prognostic impact of circulating monocyte subsets in glioblastoma patients

  Michelucci, A.

  Scailyte

  1/04/23 → 31/03/25

  Project: Research

• CANBIO2 (Maryna Chepeleva): Deconvolution of complex molecular signals of metabolomics and transcriptomics for predicting drug sensitivity and therapy resistance in malignant melanoma

  Nazarov, P. & Chepeleva, M.

  FNR - Fonds National de la Recherche

  1/03/23 → 28/02/27

  Project: Research

  • Deconvolution 100%
  • Metabolomics 99%
  • Biomarkers 81%
  • Data integration 74%
  • Data Sharing 73%

• iNEW: Role for the Itaconate/Nrf2 axis in metabolic and epigenetic reprogramming of neonatal macrophages

  Meiser, J. & Ohl, K.

  1/03/23 → 31/05/25

  Project: Research

  • itaconic acid 100%
  • Macrophages 62%
  • Epigenomics 53%
  • Phenotype 28%
  • Newborn Infant 27%

• ATLANTIS: Targeting homologous recombination and replication stress in glioblastoma: from molecular insights to synthetic lethality approaches

  Van Dyck, E. & Yi, T.

  FNR - Fonds National de la Recherche

  1/03/23 → 28/02/27

  Project: Research

• Nextimmune-2 (Mónica Miranda de la Maza): Impact of the interplay between microglia, astrocytes and infiltrating immune cells in neuroinflammatory mechanisms in Alzheimer’s disease.

  Mittelbronn, M., Bouvier, D. S. & Miranda de la Maza, M.

  FNR - Fonds National de la Recherche

  1/02/23 → 31/01/27

  Project: Research

  • Microglia 100%
  • Astrocytes 90%
  • Alzheimer Disease 83%
  • Microscopy 49%
  • Coculture Techniques 39%

• CombiN (Elisabetta Bartolini): Improving the Therapeutic benefit of immunotherapy in Neuroblastoma by combining autophagy inhibitor and anti-PD-i

  Janji, B. & Bartolini, E.

  Stiftelsen Cancera

  1/02/23 → 31/01/27

  Project: Research

• TARGET-CLL: DEVELOPMENT OF NEW TOOLS AND THERAPEUTICS FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

  Moussay, E., Paggetti, J. & Viry, E.

  1/02/23 → 31/01/25

  Project: Research

• CANBIO2 (Chloé Duculty): Overcoming treatment resistance with new therapeutic opportunities in leukaemia

  Moussay, E. & Duculty, C.

  FNR - Fonds National de la Recherche

  1/01/23 → 31/12/26

  Project: Research

  • Leukemia 100%
  • Genetic Models 63%
  • Carbon 56%
  • Drug Resistance 52%
  • Nucleotides 46%

• 1cRedox: Targeting ALDH1L2 to enforce ER-stress sensitivity of cancer

  Becker, B.

  1/11/22 → 31/10/24

  Project: Research

• ACTIDRUG: High-content drug screening to inhibit actin cytoskeleton-mediated cancer immune evasion

  Thomas, C. & Mgrditchian, T.

  1/10/22 → 30/09/24

  Project: Research

  • Immune Evasion 100%
  • Preclinical Drug Evaluations 85%
  • Actin Cytoskeleton 78%
  • Neoplasms 41%
  • Actins 38%

• EPIPHARM: IMPACT OF EPITRANSCRIPTOMIC REGULATION ON RESPONSE TO PHARMACOLOGICAL TREATMENTS IN GLIOMAS

  Golebiewska, A., Fritah, S. & Niclou, S.

  Fondation de Luxembourg

  1/10/22 → 30/09/24

  Project: Research

• CANBIO2 (PRG Management): CANBIO2

  Niclou, S. & Meiser, J.

  1/10/22 → 30/06/29

  Project: Research

  • Tumors 100%
  • Ecosystems 69%
  • Macrophages 27%
  • Endothelial cells 24%
  • Fibroblasts 23%

• Pseudo PET: Pseudo PET imaging of brain tumor hypoxia

  Keunen, O. & Niclou, S.

  1/10/22 → 30/09/24

  Project: Research

  • Tumor Hypoxia 100%
  • Brain Hypoxia 98%
  • Brain Neoplasms 70%
  • Positron-Emission Tomography 70%
  • Magnetic Resonance Imaging 42%

• CraNE: Creation of National Comprehensive Cancer Centres and EU Networking

  Niclou, S.

  1/10/22 → 30/09/24

  Project: Research

  • Translational Medical Research 100%
  • Neoplasms 77%
  • Epidemiology 69%
  • Environmental Health 54%
  • Occupational Health 48%

• KILLERCD4-CLL: CYTOTOXIC CD4+ T CELLS AS NOVEL IMMUNOTHERAPY IN CLL AND OTHER B-CELL MALIGNANCIES

  Paggetti, J., Moussay, E. & Borne, C.

  1/10/22 → 30/09/24

  Project: Research

• 4.UNCAN.eu: A Coordination and Support Action to prepare UNCAN.eu platform

  Michel, T. & Niclou, S.

  1/09/22 → 30/11/23

  Project: Consultancy

  • Neoplasms 100%
  • Data Science 61%
  • Computer Security 61%
  • Survivorship 53%
  • Formal Social Control 44%

• 1cFlex: Understanding the Flexibility of 1C metabolism and its role during metastatic dissemination of cancer cell

  Meiser, J., Letellier, E. & Chen, O.

  Collaboration Fondation Cancer - FNR

  1/09/22 → 30/09/26

  Project: Research

  • Neoplasms 100%
  • Metabolic Networks and Pathways 73%
  • Tumor Escape 49%
  • Second Primary Neoplasms 41%
  • Life Expectancy 36%

• PreCyse: Predictive biomarker profile for tumour and patient stratification for CyPep-1 guided ICI-therapy

  Janji, B. & Poussard, M.

  FNR - Fonds National de la Recherche

  1/09/22 → 30/11/25

  Project: Research

  • Immunotherapy 100%
  • Tumor Biomarkers 88%
  • Clinical Trials 55%
  • Biomarkers 36%
  • Neoplasms 36%

• I2TRON Vanessa Klapp: Immunotherapies and drug screening in improved patient-derived models: a translational approach towards personalized treatments for leukaemia

  Paggetti, J., Klapp, V. & Moussay, E.

  FNR - Fonds National de la Recherche

  1/09/22 → 30/08/26

  Project: Research

  • prohibitin 100%
  • Messenger RNA 83%
  • B-Cell Chronic Lymphocytic Leukemia 67%
  • Flavagline 63%
  • Pharmacological Metabolism 49%

• GLIORESOLVE: Training of next generation of European glioblastoma (translational) researchers, to resolve precision targeting of the brain tumour microenvironment

  Golebiewska, A., Niclou, S. & de Lucas Sanz, M.

  European Commission

  1/09/22 → 31/08/25

  Project: Research

  • Tumor Microenvironment 100%
  • Glioblastoma 71%
  • Brain Neoplasms 67%
  • isocitric acid 44%
  • Research Personnel 41%

• Synapodia: Novel synaptic filopodium-like protrusions (SFPs) protect tumor cells against cytotoxic lymphocyte-mediated killing

  Thomas, C., Filali, L. & Moreau, F.

  FNR - Fonds National de la Recherche, Fondation Cancer

  15/07/22 → 14/10/24

  Project: Research

  • Pseudopodia 100%
  • Actins 90%
  • Lymphocytes 75%
  • Immunological Synapses 53%
  • Neoplasms 40%

• DIOMEDES: Deconvolution of heterogeneity in the Glioblastoma cellular ecosystem for understanding treatment resistance and improving patient stratification

  Golebiewska, A., Nazarov, P., Mittelbronn, M., Skupin, A., Zinovyev, A., Bjerkvig, R., Brown, D., Lukashiv, T., Nosirov, B. & Dording, C.

  FNR - Fonds National de la Recherche, Fondation Cancer

  1/07/22 → 30/06/25

  Project: Research

  • Glioblastoma 100%
  • Ecosystem 84%
  • Therapeutics 21%
  • Datasets 15%
  • Tumor Microenvironment 13%

• EVceptor: Role of chemokine receptor-bearing extracellular vesicles in leukaemia and lymphoma

  Chevigne, A., Paggetti, J., Szpakowska, M. & Bonnemain-Pascual, H.

  FNRS - Fonds National de la Recherche Scientifique

  1/05/22 → 30/04/24

  Project: Research

  • Extracellular Vesicles 100%
  • Chemokine Receptors 95%
  • Lymphoma 70%
  • Leukemia 69%
  • Chemokine CXCL12 54%

• C2I: CHECKPOINT INHIBITORS IMPROVEMENT FOR THE TREATMENT OF CANCER

  Janji, B., Gao, R. & Van Moer, K.

  FNR - Fonds National de la Recherche

  1/04/22 → 31/10/25

  Project: Research

  • Immunotherapy 100%
  • Neoplasms 40%
  • Survival 31%
  • Antibodies 31%
  • Immune System 22%

• INCITE: Investigating the role of CMTM proteins in the regulation of PD-L1 expression

  Janji, B.

  FNRS - Fonds National de la Recherche Scientifique

  1/04/22 → 30/08/24

  Project: Research

  • Ligands 100%
  • Epithelial-Mesenchymal Transition 84%
  • Hypoxia 42%
  • Programmed Cell Death 1 Receptor 38%
  • T-Lymphocytes 33%

• RNA Therapeutic: In search of RNA Therapeutic Drugs in Oncology

  Fritah, S., Golebiewska, A. & Adiamah, M.

  1/03/22 → 28/02/24

  Project: Research

  • Luxembourg 100%
  • RNA 43%
  • Pharmaceutical Preparations 25%
  • Therapeutics 10%

• SUNRISE (TLV-PDR-2021): TARGETING TUMOR PROPAGATING CELLS IN GLIOBLASTOMA: FROM MECHANISTICINSIGHTS TO PRECISION MEDICINE

  Van Dyck, E., Rogister, B., Neirinckx, V., Nazarov, P. & Pailas, A.

  Fondation du Pélican de Mie et Pierre Hippert-Faber, FNRS - Fonds National de la Recherche Scientifique

  1/03/22 → 28/02/26

  Project: Research

  • Glioblastoma 100%
  • Stem Cells 50%
  • Precision Medicine 46%
  • Lateral Ventricles 43%
  • DNA Repair 36%

• NIMBUS: Roles of the epigenetic reader MBD1 in IDH1-mutated gliomas

  Van Dyck, E. & Fritah, S.

  FNRS - Fonds National de la Recherche Scientifique

  17/01/22 → 16/10/24

  Project: Research

• RESCOM-2021: 5th Lecture Series in Cancer Research

  Niclou, S. & Janji, B.

  FNR - Fonds National de la Recherche

  3/01/22 → 31/12/24

  Project: Other

  • Neoplasms 100%
  • Health Services Research 67%
  • Luxembourg 47%
  • Biological Science Disciplines 36%
  • Translational Medical Research 33%

• CancerProfile: Predictive and personalized medicine of pancreatic cancer

  Mittelbronn, M.

  1/01/22 → 30/01/26

  Project: Research

  • Personalized medicine 100%
  • Biopsy 90%
  • Tumors 70%
  • Chemotherapy 51%
  • Biomarkers 43%

• TRICK-ALDH: Assessment the impact of selective ALDH1 inhibitors on tumor infiltrating lymphocytes and the therapeutic benefit of Immune checkpoint blockers

  Berchem, G., Janji, B. & Kumar, A.

  Advanced BioDesign

  1/01/22 → 30/06/24

  Project: Research

  • Immunotherapy 100%
  • Tumor-Infiltrating Lymphocytes 96%
  • Survival 62%
  • Neoplasms 61%
  • Multiple Drug Resistance 39%

• IMPACT 21: IMPROVING CANCER IMMUNOTHERAPY BY TARGETING HYPOXIA

  Janji, B. & Benoit, A.

  FNRS - Fonds National de la Recherche Scientifique

  1/11/21 → 1/12/25

  Project: Research

  • Immunotherapy 100%
  • Hypoxia 89%
  • Neoplasms 43%
  • Tumor Microenvironment 33%
  • Tumor Escape 21%

• I2TRON Kim Eiden: The role of mitochondrial folate metabolism during macrophage polarization (Mac1L)

  Meiser, J. & Eiden, K.

  FNR - Fonds National de la Recherche

  15/10/21 → 14/10/25

  Project: Research

• TERMINI: Roles of NEIL3 DNA glycosylase in telomere dynamics and DNA demethylation in glioblastoma: From molecular insights topreclinical target validation

  Van Dyck, E. & Baidarjad, H.

  FNR - Fonds National de la Recherche, Lions Clubs International

  1/07/21 → 30/06/24

  Project: Research

  • Telomere 100%
  • DNA Glycosylases 97%
  • Glioblastoma 83%
  • DNA Demethylation 52%
  • Telomerase 25%

• GLASS-LUX: Glioma Longitudinal AnalySiS in Luxembourg (GLASS-LUX): ex vivo and in vivo Functional Profiling of Recurrent Gliomas

  Golebiewska, A., Niclou, S., Nazarov, P., Kwon, Y., Klink, B. & Krokhmal, I.

  Collaboration Fondation Cancer - FNR , FNR - Fonds National de la Recherche

  1/06/21 → 31/12/25

  Project: Research

  • Luxembourg 100%
  • Glioma 80%
  • Epigenomics 16%
  • Pharmaceutical Preparations 10%
  • Organoids 8%

• ImmoGBM: ImmoGBM

  Golebiewska, A., Bours, V., Robe, P., Rezaeipour, M. & Niclou, S.

  FNRS - Fonds National de la Recherche Scientifique

  1/06/21 → 31/05/25

  Project: Research

• PFP: Personalized Functional Profiling - PFP

  Mittelbronn, M. & Michel, T.

  1/05/21 → …

  Project: Research

  • Neoplasms 100%
  • Luxembourg 90%
  • Precision Medicine 60%
  • Drug Repositioning 38%
  • Therapeutics 32%

• MelCol_PFP: PERSONAL FUNCTIONAL PROFILING FOR DRUG DISCOVERY IN MELANOMA AND COLORECTAL CANCER

  El Khoury, V. & Cutrona, M.

  FNR - Fonds National de la Recherche

  1/04/21 → 31/03/25

  Project: Research

• I2TRON Elena Ockfen: Biological and clinical implications of PD-L1 protein polarization at the tumor tissue and cell levels

  Thomas, C. & Ockfen, E.

  FNR - Fonds National de la Recherche

  1/03/21 → 28/02/25

  Project: Research

• I2TRON Frida Lind-Holm Mogensen: Microglia programs under PARK7/DJ-1 deficiency, a genetic cause of Parkinson’s disease

  Michelucci, A. & Lind-Holm, F.

  FNR - Fonds National de la Recherche

  15/02/21 → 14/02/25

  Project: Research

• I2TRON Pilar Moreno : Precision medicine for Glioblastoma patients: a patient-based pre-clinical platform for immuno-oncology

  Golebiewska, A., Niclou, S. & Moreno Sanchez, P. M.

  FNR - Fonds National de la Recherche

  1/02/21 → 31/01/25

  Project: Research

• TRANSACTINg: Unraveling the genetic pathways underlying actin remodeling-mediated cancer immune evasion

  Thomas, C., Skupin, A. & Krecke, M.

  FNRS - Fonds National de la Recherche Scientifique

  1/01/21 → 31/12/24

  Project: Research

  • Immune Evasion 100%
  • Actins 82%
  • Neoplasms 34%
  • Lymphocytes 18%
  • Immunotherapy 17%

• EATRIS-Plus: Consolidating the capacities of EATRIS-ERIC for Personalised Medicine

  Ammerlaan, W., Marchese, M., Beaumont, K. & Nazarov, P.

  European Commission

  1/10/20 → 1/12/23

  Project: Research

• ACTIVASION: Actin cytoskeleton remodeling in tumor immune evasion - mechanisticaspects

  Thomas, C.

  FNR - Fonds National de la Recherche

  15/07/20 → 14/02/24

  Project: Research

  • Immunological Synapses 100%
  • Natural Killer Cells 87%
  • Tumor Escape 69%
  • Actins 66%
  • Actin Cytoskeleton 64%

• SMART GLIOBLASTOMA: SMART GLIOBLASTOMA: Signaling and Modulation of the AtypicalIsoform of the CXCR3 RecepTor in glioblastoma cells

  Chevigne, A., Niclou, S., Rogister, B., Hanson, J. & D'Uonnolo, G.

  FNRS - Fonds National de la Recherche Scientifique

  15/05/20 → 14/10/24

  Project: Research

  • CXCR3 Receptors 100%
  • Glioblastoma 79%
  • Protein Isoforms 50%
  • Chemokine Receptors 19%
  • Brain Neoplasms 16%